Direct Line April 2026: Stopping Ozempic and Lifting With Osteopenia

Stop a GLP-1 and about two thirds of the weight loss comes back within a year. Three randomized withdrawal trials (SURMOUNT-4, STEP 1 extension, STEP 4) and a new BMJ 2026 systematic review of 37 RCTs and nearly 10,000 adults all land on the same signal. The cardiometabolic benefits, blood pressure, fasting glucose, lipids, drift back in parallel with the weight. The framing that actually fits the data: GLP-1s behave like a statin. There is a cumulative benefit during exposure, but this does not extend indefinitely, This month's Direct Line covers two subscriber questions. The first asks what the new BMJ paper on GLP-1 cardiovascular protection after cessation actually shows, and how GLP-1 durability compares to lifestyle-only interventions. The second asks how a postmenopausal woman newly diagnosed with osteopenia should structure her lifting. Studies referenced: SURMOUNT-4 (Jastreboff, JAMA 2024), STEP 1 extension (Wilding, Diabetes Obes Metab 2022), STEP 4 (Rubino, JAMA 2021), West et al. BMJ 2026 systematic review, Budini 2026 eClinicalMedicine regain meta-analysis, SELECT cardiovascular outcomes, FLOW renal outcomes, the Diabetes Prevention Program, Look AHEAD, POUNDS Lost, and LIFTMOR (Watson, JBMR 2018). Full episode on BBM+ covers 8 additional subscriber questions. Join at Timestamps 0:00 Intro 1:52 Q1: What happens when you stop a GLP-1 5:33 Lifestyle-only comparators: DPP, Look AHEAD, POUNDS Lost 8:15 Austin on the cessation conversation 1 2:41 BMJ 2026: weight and cardiometabolic regression 17:59 The statin framing 23:41 Austin: first 6 months off GLP-1 28:07 Q2: Osteopenia and heavy lifting 35:28 LIFTMOR protocol 38:00 Outro Next Steps For evidence-based resistance training programs: barbellmedicine.com/training-programs For individualized training consultation: barbellmedicine.com/coaching Explore our full library of articles on health and performance: barbellmedicine.com/resources To consult with Drs. Baraki or Feigenbaum email us at support@barbellmedicine.com Resources Aronne, Louis J., et al. "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial." JAMA , vol. 331, no. 1, 2024, pp. 38–48. Wilding, John P. H., et al. "Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: The STEP 1 Trial Extension." Diabetes, Obesity and Metabolism , vol. 24, no. 8, Aug. 2022, pp. 1553–1564. Rubino, Domenica, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial." JAMA , vol. 325, no. 14, 2021, pp. 1414–1425. West, Sam, et al. "Weight Regain After Cessation of Medication for Weight Management: Systematic Review and Meta-Analysis." BMJ , vol. 392, 7 Jan. 2026, article e085304. Budini, Brajan, et al. "Trajectory of Weight Regain After Cessation of GLP-1 Receptor Agonists: A Systematic Review and Nonlinear Meta-Regression." eClinicalMedicine , vol. 93, 4 Mar. 2026, article 103796. Lincoff, A. Michael, et al. "Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes." New England Journal of Medicine , vol. 389, no. 24, 11 Nov. 2023, pp. 2221–2232. Perkovic, Vlado, et al. "Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes." New England Journal of Medicine , vol. 391, no. 2, 24 May 2024, pp. 109–121. Knowler, William C., et al. "Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin." New England Journal of Medicine , vol. 346, no. 6, 7 Feb. 2002, pp. 393–403. Look AHEAD Research Group. "Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes." New England Journal of Medicine , vol. 369, no. 2, 11 July 2013, pp. 145–154. Sacks, Frank M., et al. "Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates." New England Journal of Medicine , vol. 360, no. 9, 26 Feb. 2009, pp. 859–873. Watson, Shelley L., et al. "High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial." Journal of Bone and Mineral Research , vol. 33, no. 2, 2018, pp. 211–220. Our Sponsors: * Check out FIGS and use my code wearfigs.com for a great deal: * Check out Factor and use my code factormeals.com/bbm50off for a great deal: * Check out Quince and use my code quince.com/bbm for a great deal: Advertising Inquiries: Privacy & Opt-Out:

You can listen to Direct Line April 2026: Stopping Ozempic and Lifting With Osteopenia online on Radio and Podcast. Open the player on this page to stream the available audio.

Direct Line April 2026: Stopping Ozempic and Lifting With Osteopenia is an episode from Barbell Medicine Podcast by Barbell Medicine.

This episode is 38:39 long.

This episode was published on Apr 21, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Barbell Medicine Podcast when more episodes are available from the podcast feed.